Eli Lilly (LLY)’s GLP-1 Empire: A Deep Dive Into the $947B Pharmaceutical Giant
Lilly posts 56% Q1 revenue growth, raises guidance to $85B, and has a triple-agonist weight-loss drug in the wings. Is $1,000 the new floor?
Quick overview
- Eli Lilly reported a remarkable Q1 2026 with revenues of $19.8 billion, a 56% increase year-on-year, and adjusted EPS of $8.55, surpassing expectations by 28%.
- The company's growth is primarily driven by two drugs, Mounjaro and Zepbound, which together command a 60.1% share of the U.S. GLP-1 market.
- CEO David Ricks is focusing on international markets for future growth, with international revenue rising 81% in Q1 2026.
- Analysts remain bullish on Eli Lilly, with a consensus price target of $1,218, indicating a potential 21% upside from current levels.
Eli Lilly just delivered one of the most dominant quarterly beats in recent pharmaceutical history. Q1 2026 revenue hit $19.8 billion — 56% higher than a year ago and 12.5% above analyst estimates. Adjusted EPS of $8.55 crushed expectations of $6.66 by a staggering 28%. Net income surged 168% year-on-year to $7.4 billion.
The company immediately raised its full-year revenue guidance by $2 billion, now targeting $82–$85 billion for 2026. Adjusted EPS guidance stands at $35.50–$37.00. Investors reacted decisively — the stock jumped over 10% on earnings day.
Eli Lilly’s Growth Story: Two Drugs Doing the Heavy Lifting
The entire growth story runs through two products: Mounjaro and Zepbound. Mounjaro, the diabetes treatment, pulled in $8.66 billion in Q1 — up 125% year-on-year. U.S. sales reached $4.2 billion. International revenue nearly quadrupled, from $1.2 billion to $4.4 billion, with China’s addition of Mounjaro to its National Reimbursed Drug List acting as a major catalyst.
Zepbound, the obesity drug, generated $4.16 billion in U.S. revenue, up 80%. Lower realised prices were a headwind, but volume gains more than compensated. Together, these two drugs have handed Lilly a commanding 60.1% share of the U.S. GLP-1 market. Novo Nordisk, despite its first-mover advantage with Wegovy, trails at 39.4%.
Is Going International the Next Leg of Growth?
CEO David Ricks is pointing investors toward global markets as the next major revenue driver. International revenue jumped 81% to $7.7 billion in Q1, powered by a 95% surge in volume. Ricks noted the company is now in its third or fourth quarter of launches across major international markets, having resolved supply constraints from late 2024.
Organic demand outside the U.S. is accelerating. Patients in Europe, China, and Brazil are paying out-of-pocket — a signal of genuine consumer pull, not just insurer-driven adoption.
Oral GLP-1 Pill Changes the Game
In April 2026, Lilly launched Foundayo — the first oral GLP-1 pill that can be taken any time of day, without food or water restrictions. Over 20,000 patients started the drug in its first few weeks, with more than 1,000 new patients daily. The critical data point: 80% of Foundayo users were entirely new to GLP-1 medications. That’s market expansion, not cannibalisation.
Foundayo also delivered superior diabetes control versus oral semaglutide in head-to-head Phase 3 trials published in The Lancet. There is one flag to watch: the FDA disclosed a liver failure report tied to Foundayo in early May 2026. It hasn’t yet escalated into a crisis, but regulatory scrutiny on a key growth driver deserves close monitoring.
The Real Option Value: Eli Lilly’s Retatrutide
The most compelling part of the Lilly story is what hasn’t launched yet. Retatrutide is a “triple agonist” — it targets GLP-1, GIP, and glucagon receptors simultaneously. Zepbound, the current flagship, is a dual agonist targeting GLP-1 and GIP. Adding glucagon receptor activation is a meaningful pharmacological step forward, and Phase 3 data backs it up with significant reductions in A1C and weight loss.
Novo Nordisk, by comparison, is still developing its own dual agonist. Lilly could launch a triple agonist before its rival even closes the dual-agonist gap. Retatrutide is months to a year away from launch, but its commercial potential is already being priced into analyst targets.
LLY Technical Analysis: What the Chart Says
LLY trades at $1,004.92 — roughly in the middle of its 52-week range of $623.78 to $1,133.95. The stock is up 38% over the past year but remains about 11% below its all-time high.
The technical picture after the Q1 earnings surge is constructive but not without friction:
- RSI near 65–70 — strong post-earnings momentum, approaching but not yet in overbought territory
- MACD positive and trending bullish — signal line crossover confirms the upward move
- 50-day moving average near $940 — price well above, a bullish alignment
- 200-day moving average near $997 — the critical battleground; LLY is hovering right at this level
Holding above $997 is the key near-term test. A clean close above and through confirms the breakout. A slip below would signal the post-earnings pop is fading and invite a retest of the $940–$960 zone. Resistance sits at the prior 52-week high of $1,133.
Volume on earnings day was high, lending credibility to the move. The chart is setting up three plausible paths.
- Bull case: LLY holds $1,000, reclaims the $1,133 high. Retatrutide launch timing becomes clearer. Medicare obesity coverage expands. GLP-1 users grow from 20 million to 30 million globally by end of 2026. Wall Street re-rates toward $1,300+.
- Base case: Consolidation between $940–$1,100. Guidance proves conservative. Foundayo adoption continues steadily. Pricing pressure is offset by volume. The stock grinds toward analyst consensus of $1,218.
- Bear case: Foundayo safety concerns escalate into regulatory action. Drug pricing negotiations bite harder than expected. Novo Nordisk closes the competitive gap faster than anticipated. LLY breaks below $940 and retests the $850–$900 zone.
Key Risks the Eli Lilly (LLY) Bulls Can’t Ignore
Lilly’s story is powerful, but it comes with real vulnerabilities:
- Realised prices fell 13% overall and 25% outside the U.S. in Q1. Government drug pricing negotiations could accelerate this headwind materially.
- The Foundayo liver failure report is an early-stage concern that warrants watching.
- At 36x trailing earnings, the valuation leaves almost no room for a growth miss.
- Novo Nordisk is not standing still. A pill-based Wegovy is already live. A dual agonist is in development.
LLY Stock Outlook: Wall Street’s Verdict
Analyst consensus leans firmly bullish. Of 30 analysts covering LLY, 23 rate it a Buy, 2 a Strong Buy, 4 a Hold, and 1 a Sell. The average price target is $1,218 — implying roughly 21% upside from current levels. The high-end targets sit at $1,344 from Morgan Stanley and $1,325 from Wolfe Research.
What’s Next for Eli Lilly Investors?
Lilly’s fundamentals are exceptional. The GLP-1 structural growth story — driven by genuine patient demand, market expansion, and a superior drug pipeline — is one of the most compelling long-term investment theses in the market today. CEO David Ricks estimates global GLP-1 users could grow from 20 million at end-2025 to 30 million by end-2026.
But at $1,005 a share, the stock already reflects a great deal of good news. The post-earnings surge pushed RSI into elevated territory, and the 200-day moving average is the line in the sand. For long-term investors, conviction remains warranted. For those looking to add exposure now, the smarter move is to wait for the stock to either consolidate cleanly above $1,000 or pull back to the $940–$960 support zone before sizing up.
Retatrutide’s NDA filing timeline is the next potential re-rating catalyst. Watch for it.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
- Read our latest reviews on: Avatrade, Exness, HFM and XM
Related Articles
Sidebar rates
Related Posts
Save
